Empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, did not show significant benefit in reducing a first heart failure (HF) hospitalization or death from any cause in patients at high risk for HF after an acute myocardial infarction (MI), in the randomized EMPACT-MI trial.
The results were presented April 6 here at the American College of Cardiology (ACC) Scientific Sessions 2024 and simultaneously published online in the New England Journal of Medicine.
However, a prespecified secondary analysis, also simultaneously published online in Circulation, showed the risks for a first HF hospitalization and total HF hospitalizations were significantly lower with empagliflozin versus placebo among vulnerable patients.
Menu